Such inhibitors would be helpful tools in validating the p130Cas-Crk/CrkL as a potential therapeutic target for invasive cancers in which Crk, CrkL, and p130Cas play critical roles in tumor cell migration and invasion. The gene discussed is BCAR1; the disease is cancer.